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The anti-glycemic drug metformin, widely prescribed as first-line
treatment of type II diabetes mellitus, has lifespan-extending
properties. Precisely how this is achieved, remains unclear. Via
a quantitative proteomics approach using the model organism
Caenorhabditis elegans, we gained molecular understanding of
the physiological changes elicited by metformin exposure, includ-
ing changes in branched-chain amino acid catabolism and cuticle
maintenance. We show that metformin extends lifespan through
the process of mitohormesis and propose a signaling cascade in
which metformin-induced production of reactive oxygen species
(ROS) increases overall life expectancy. We further address an
important issue in aging research, wherein so far, the key molec-
ular link that translates the ROS signal into a pro-longevity cue
remained elusive. We show that this beneficial signal of the mi-
tohormetic pathway is propagated by the peroxiredoxin PRDX-2.
Because of its evolutionary conservation, peroxiredoxin signaling
might underlie a general principle of pro-longevity signaling.
Aging j Metformin j Peroxiredoxin j Proteomics j Reactive oxygen
species
Introduction
Metformin, an anti-glycemic biguanide drug and the most com-
mon treatment of type II diabetes mellitus, has life-extending
capabilities (1, 2). Several other human diseases, such as cancer
(3) and nonalcoholic fatty liver disease (4) are also potentially
alleviated by metformin treatment. This suggests that metformin
acts on common pathways involved in a spectrum of aging-related
disorders. Because of its demonstrated beneficial effect on lifes-
pan in the nematode Caenorhabditis elegans (5, 6), and in the
rodents Rattus norvegicus (1) andMus musculus (2), these models
facilitate research into the underlying mode of action.
It has been hypothesized that metformin elicits its benefi-
cial effects by mimicking dietary restriction (DR) (7), a regimen
wherein a physiological response is triggered by reducing the
uptake of nutritive calories. The physiological response to DR
causes lifespan extension and delays age-dependent decline from
yeast to primates (8). The idea of similarity sprouts from the
observed low blood glucose and insulin levels combined with
increased glucose utilization in both calorically restricted and
metformin-treated animals (7). In addition, metformin-treated
worms show phenotypes similar to DR worms (5), and transcript
profiles of metformin-treated and DR mice also overlap signifi-
cantly (9).
Caution is due, however, in referring toDR, because different
methods to induceDR inC. elegans act through different genes to
elicit corresponding effects on lifespan (10–12). Glucose restric-
tion, a specific type of DR, requires the adenosine monophos-
phate (AMP)-dependent kinase (AMPK) to extend lifespan. Ac-
tivation of AMPK leads to increased mitochondrial production
of reactive oxygen species (ROS), which induces stress defense
and results in a net increase in longevity. This process of lifespan
extension based on mitochondrial oxidative stress, is known as
mitohormesis (13).
Despite its similarities to DR and its widespread use as an
anti-glycemic drug, the actual mode of action of metformin is
largely unknown and a subject of much debate. In mammals,
metformin is generally believed to act through the activation of
AMPK, one of the main regulators of cellular energy homeostasis
(2, 14–16), but recent research suggests the existence of AMPK-
independent mechanisms as well (17, 18). More upstream, met-
formin is thought to activate AMPK through partial inhibition of
complex I of the electron transport chain (ETC) and a resultant
increase in the AMP/ATP ratio (19–21), though again, not all
data support this theory (16, 22). Important players inmetformin-
induced lifespan extension in C. elegans are the liver kinase
B1 ortholog PAR-4, the AMPK ortholog AAK-2 and the SKN-
1 transcription factor, which is involved in activating phase II
detoxificationmechanisms (5). It has recently been demonstrated
that in C. elegans, metformin partly elicits its effects through
altering the folate metabolism of its microbial food source (6),
but questions about its direct effects are largely unaddressed.
It is for instance unclear how metformin induces AAK-2 and
SKN-1 activity. Overall, many gaps remain in our knowledge of
metformin-induced lifespan extension.
In order to study the targets of metformin, we performed a
proteomic analysis on metformin-treated C. elegans and used the
results as a framework for follow-up experiments. We observed
striking similarities between metformin-treated and glucose-
restricted worms and discovered several novel factors involved
in mitohormetic regulation of lifespan, including a role for the
Significance
Recently it has been suggested that metformin, the most
commonly used anti-diabetic drug, might also possess general
health-promoting properties. Elucidating metformin's mode
of action will vastly increase its application range, and will
contribute to healthy aging. We reveal a signaling cascade in
which metformin is able to extend lifespan by increasing the
production of reactive oxygen species (ROS). This allowed us
to further work at the crossroads of human disease and aging
research, identifying a key molecule that is able to translate
the ROS signal into a pro-longevity cue: an antioxidant perox-
iredoxin is also able to activate a lifespan-promoting signaling
cascade, here described in detail. Continued research efforts
in this field lead towards a targeted improvement of aging-
related complications.











































































































































Table 1. Functional analysis of differential proteins
Functional analysis of differential proteins
Pathway enrichment of upregulated proteins1
Pathway p-value
Valine, leucine and isoleucine
degradation
9.85E-09
Citrate cycle (TCA cycle) 1.38E-04
Glycolysis / Gluconeogenesis 2.47E-04
Pyruvate metabolism 4.62E-04
Functional clustering2












Catabolism and respiration 2.07
NAD binding and reduction 1.99
Cytoskeleton organization 1.39






Biosynthetic processes (DNA/RNA) 1.39
Functional analysis of the differential proteomics data. All enrichment
analyses were performed using the Database for Annotation, Visualisation
and Integrated Discovery (DAVID) (23). 1Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways overrepresented (p < 0.05) in the group of
proteins upregulated after metformin treatment. 2Functional clustering of
proteins, which are significantly altered after metformin treatment. The
reported enrichment score was calculated by DAVID based on the Fisher
Exact score of each clustered term. The higher the value, the more enriched
the cluster. Only clusters with an enrichment score higher than 1 were
reported. Complete information can be found in Dataset S1.
Fig. 1. Metformin treatment does not induce the mitochondria-specific un-
folded protein response (UPRmt). Day 1 adult metformin-treated hsp-6::GFP
worms show no difference in fluorescence when compared to untreated
control worms. hsp-6::GFP worms were exposed to cco-1 RNAi as a positive
control. cco-1 encodes a cytochrome c oxidase subunit, an integral part of
the mitochondrial electron transport chain (24).
mitochondrial peroxiredoxin PRDX-2, which appears to be re-
sponsible for translating oxidative stress into a downstream pro-
Fig. 2. Metformin increases lifespan according to the principle of mito-
hormesis, for which it requires PRDX-2. A Metformin treatment increases
metabolic heat production (p < 0.01**; n = 3 for untreated and n = 4 for
treated worms) and respiration (p < 0.05*; n = 3). Bars represent mean ±
SEM. B Metformin induced a significant increase in H2O2 release in day 1
adult worms after both continuous exposure during development (p < 0.05*;
n = 7) and after 24 hours of exposure, starting from the young adult stage
(p < 0.05*; n = 7 for untreated and n = 5 for treated worms). Exposing
the worms for 4 hours before measurement did not result in a significant
increase (p > 0.05n.s.; n = 7). Bars represent mean ± SEM. C The antioxidant N-
acetylcysteine (NAC) abolishes the lifespan extending effect of metformin (p
< 0.001***; n ≥ 169 for each curve, see Table S1). D prdx-2 is required for
metformin-induced lifespan extension. Metformin treatment significantly
reduces lifespan of prdx-2 mutants (p < 0.001***; n ≥ 127 for each curve,
see Table S1). E Metformin treatment promotes the formation of PRDX-2
disulfide dimers (p < 0.01**), implied to function in signal transduction. Bars
represent mean ± SEM (n = 4). F PRDX-2 is required for metformin-induced
phosphorylation of the p38MAP kinase PMK-1. Metformin treatment of wild
type worms induced phosphorylation of PMK-1, inferred from a larger band
observed on the Western blot. This metformin-mediated induction of PMK-1
phosphorylation is absent in prdx-2 knockout worms. Histone H3 levels were
used as a loading control.
longevity signal. In addition to lifespan extension, we also report
features that contribute to the healthspan of metformin-treated
worms.
Results
Molecular changes in Caenorhabditis elegans upon metformin
exposure: a proteomic approach
In order to gain a deeper understanding of the physiological
changes elicited by metformin exposure, a differential gel-based
proteomics experiment was performed. A total of 164 spots with
differential abundances were detected, 134 of which could be











































































































































Fig. 3. Metformin inhibits Complex I of the electron transport chain (ETC) in a way distinct from rotenone. AMetformin inhibits complex I but not complex
II based respiration. Higher values for O2 flux indicate higher respiration, negative values indicate a small influx of O2, usually due to the injection of a
compound. The effect of metformin on mitochondrial respiration was measured by sequentially adding compounds to stimulate different parts of the ETC.
Green arrows indicate compounds that were added in both the control and metformin-treated cells; red arrows indicate compounds that were only added in
the treated cell. After adding an equal volume of mitochondria (↓start), metformin was added to one of the cells (↓metformin). Subsequently, the complex I
substrates pyruvate and malate (↓P+M) were added, followed by the addition of ADP (↓ADP), initiating electron transport from complex I. Metformin-treated
mitochondria clearly fail to initiate complex I based respiration, thus indicating that metformin inhibits electron transport from complex I in vitro. Finally,
the complex II substrate succinate (↓S) was added to the metformin-treated cell, which led to a marked increase in mitochondrial respiration, indicating that
metformin does not block electron transport from complex II. Two variations of this experiment were executed to also use the potent complex I inhibitor
rotenone as a positive control (Fig. S4A) and to add succinate to the negative control condition as well (Fig. S4B). B Mitochondria treated with metformin
produce H2O2 at a higher rate than untreated mitochondria (p < 0.001***; n = 3). Treatment with the complex I inhibitor rotenone had the opposite effect
(p < 0.001***; n = 3).
Fig. 4. Metformin induces the branched-chain amino acid (BCAA) degradation and β-oxidation pathways but the β-oxidation enzyme ACDH-1 is not required
for metformin-mediated for longevity. AMetformin treatment stimulates the BCAA degradation pathway (Fig. S5) and in turn reduces the concentration of
free BCAAs in C. elegans (p < 0.01**). Bars represent mean ± SEM (n = 6). B Metformin-treated worms show reduced fat storage (p < 0.001***; n = 30 for
untreated and n = 33 for treated worms), possibly indicating increased flux through the β-oxidation pathway. Bars represent mean ± SEM. C Deletion of
β-oxidation enzyme acdh-1 results in a proportionally larger effect of metformin on longevity (p < 0.001***; n ≥ 54 for each curve, see Table S1) .
Fig. 5. Metformin attenuates the morphological decline with aging in C. elegans A Metformin-treated worms retain a stable volume while control worms
older than 6 days start shrinking. B Electron micrograph of the cuticle of a day 9 adult non-treated wild type worm. Some deformations of the cuticle (seen
as “wrinkling”, marked with an arrow) are starting to manifest. C No structural abnormalities can be seen in a metformin-treated day 9 wild type adult.
tifications, the final analysis resulted in a list of 58 upregulated
and 30 downregulated proteins (Dataset S1).
Enrichment analysis (23) of the upregulated proteins resulted
in the detection of several overrepresented pathways (Table 1), of
which the branched-chain amino acid (BCAA) degradation path-
way was most markedly enriched. All other enriched pathways,
including glycolysis and the tricarboxylic acid (TCA) cycle, are
involved in general energy metabolism. No significant pathway
enrichment was observed in the analysis of downregulated pro-
teins. Combined analysis of all differential proteins (both up and
down) did not reveal additional pathways of interest.
Further functional clustering was used to subdivide the up-
and downregulated proteins into meaningful groups (Table 1).











































































































































Fig. 6. The mitohormetic signaling cascade as induced by metformin.
Metformin induces an increase in activity in several catabolic pathways (Fig.
S6), including the TCA cycle and β-oxidation, with β-oxidation producing
a relatively higher amount of FADH2 per cycle. This increase in substrate
allows for an increase in mitochondrial respiration, which in turn leads
to an increase in ROS production, possibly through metformin-mediated
perturbation of electron transport (marked in red). These ROS oxidize PRDX-
2 peroxiredoxins, which subsequently dimerize and enter their active state.
Active PRDX-2 will activate a conserved MAPK cascade containing the p38
MAPK PMK-1, likely leading to the activation of SKN-1 (28) and a concomitant
increase in longevity and stress protection (dashed arrows: literature-based
evidence; see Fig. S6 for more information on the pathways induced by
metformin treatment).
terms and proteins in each group, was gathered to assist in
data interpretation (Dataset S1). These results were used as the
backbone of hypothesis-driven experiments into the mechanisms
induced by metformin treatment.
Metformin does not induce mitochondrial protein unfolding
stress
Due to the marked clustering of mitochondrial proteins (Ta-
ble 1) and metformin’s putative inhibitory effect on complex I
of the ETC, it needs to be tested whether metformin is capable
of inducing the mitochondria-specific unfolded protein response
(UPRmt). This is essential because the UPRmt increases lifespan
in response to either misfolding of mitochondrial proteins or
stoichiometric abnormalities in the ETC complexes (24).
We did not observe upregulation of the UPRmt marker hsp-6
in worms exposed to metformin (Fig. 1). Additional experiments
with higher concentrations of metformin and different exposure
times, yielded similar negative results (Fig. S1). As such, lifespan
extension ofmetformin via the induction of theUPRmt is unlikely,
which suggests that the drug affects the mitochondria in another
way.
Metformin increases lifespan through hormetic phenomena
Metformin has been put forward as a possibleDRmimetic (7)
and sinceDRhas been linked tomitohormesis (13, 25), we looked
into evidence for a role for mitohormesis in metformin-induced
lifespan extension. Clustering analysis of the proteomics experi-
ments revealed a significant overrepresentation of several mito-
chondrial proteins and proteins involved in catabolism (Table 1).
These clustersmight point to an increase in respiration, one of the
hallmarks of mitohormesis (13). Indeed, upon metformin treat-
ment, we observed a significant increase in respiration (45%) and
metabolic heat production (38%) (Fig. 2A) in wild type worms.
These changes, in combination with the AMPK-dependence of
metformin-mediated longevity (5), strongly resemble the mito-
hormetic pathway (13) and might point toward an increase in
ROS production.
To verify whether mitochondrial ROS production was af-
fected by metformin treatment, we measured hydrogen peroxide
levels in metformin-treated worms. ROS production was indeed
increased (Fig. 2B), further supporting the mitohormesis hypoth-
esis. Induction of ROS production was already clear after 24
hours of exposure to metformin (Fig. 2B). This increase in ROS
seems to be an integral part of metformin-induced lifespan exten-
sion, as treatment with the potent antioxidants N-acetylcysteine
(NAC) (13) and butylated hydroxyanisole (BHA) (26) abolished
the positive effect of metformin on lifespan (Fig. 2C and Fig.
S2A). Finally, the critical phase for metformin-mediated lifespan
extension clearly resembles the critical phase for other mito-
hormetic stressors (13), as treatment with metformin starting
from adulthood onwards or during the first few days of adult-
hood only, were sufficient to increase lifespan (Fig. S2B). This is
opposed to treatment with metformin during larval development
only, which had no detectable effect on lifespan (Fig S2B).
Metformin-mediated lifespan extension requires the perox-
iredoxin PRDX-2
The mitohormetic pathway as seen during glucose restriction
is induced when low availability of glucose causes low energy lev-
els, which in turn activates AMPK (13). AMPK activity increases
catabolism and respiration, which results in the increased pro-
duction of ROS and a resultant activation of hormetic protective
mechanisms (13). The largest hiatus in this pathway is the step be-
tween the increased ROS production and the induction of stress
defense, as no molecule was put forward that might translate
the ROS signal into further downstream defense. We therefore
set out to reveal this missing link and to further complete the
hormetic signaling pathway.
Peroxiredoxins are known hydrogen peroxide scavengers and
their oxidized dimeric form is involved in the direct activation
of kinases in mammalian cells (27). As the mitochondrial perox-
iredoxin PRDX-2 was upregulated during metformin treatment
(Dataset S1), this protein is of particular interest as a potential
inductor of mitohormesis. Deletion of the prdx-2 gene results
in an extreme decrease in lifespan upon metformin treatment
(Fig. 2D). Not only did the positive effect of metformin on
lifespan disappear, the prdx-2 experimental group collapsed when
exposed tometformin. Treatment with NAC partially rescued this
deleterious effect, implying that excessive ROS production is at
least partly responsible for the detrimental effect of metformin
on these mutants (Fig. S2C). In support of these results, we
observed increased formation of PRDX-2 dimers aftermetformin
treatment (Fig. 3E, Fig. S3). Since these oxidized dimers are
likely involved in cellular signaling (27), we propose that PRDX-2
induces pro-longevity signaling during themitohormetic response
to metformin treatment.
One of the potential downstream targets of PRDX-2 is the
p38 MAP kinase PMK-1, which is involved in the activation of
the SKN-1 transcription factor (28). This transcription factor is
in turn required for metformin-mediated longevity (5). Western
blot analysis revealed a marked increase in phosphorylation of
PMK-1 after metformin treatment. In contrast, deletion of prdx-
2 resulted in an absence of metformin-induced phosphorylation
of PMK-1 (Fig. 2F). These data strongly imply that PRDX-2 is
required for PMK-1 activation after metformin treatment.
In sum, all these findings subscribe that metformin extends
lifespan via mitohormesis in C. elegans, and that PRDX-2 is an
integral part of the mitohormetic pathway.
Metformin inhibits complex I of the ETC
Metformin is generally believed to act through inhibition of
complex I of the ETC (19–21), although some recent findings cast
doubt on this (16, 22). Treatment of C. elegans with rotenone,
another complex I inhibitor, at a concentration that extends
longevity, results in a decrease in total oxygen consumption (25).











































































































































fore raises the question whether it is truly capable of inhibiting
complex I of the ETC.
We tested whether metformin is able to affect electron flow
in mitochondria extracted from C. elegans, and observed a clear
and specific inhibition of electron flow from complex I, while
the electron flow from complex II was unaffected (Fig. 3A; Fig.
S4A-B). These results, clearly mimicking the inhibitory action
of rotenone (Fig. S4A), complement our previous data only if
metformin inhibits complex I in a distinct way. To this end,
we tested whether metformin and rotenone had different ef-
fects on ROS production in mitochondria. At concentrations at
which both completely inhibit complex I respiration and after
feeding only complex I, metformin increased ROS production
while rotenone decreased it (Fig. 3B), implying a fundamental
difference between rotenone’s and metformin’s inhibitory action
on complex I.
The BCAA degradation pathway is upregulated during met-
formin treatment
The BCAAs leucine, isoleucine and valine display a cer-
tain duality in relation to health and longevity. On one hand,
their effectiveness has been noted in the treatment of liver and
cardiac diseases (29, 30) and upregulation of BCAAs is one
of the metabolic signatures of the long-lived daf-2 mutant (31,
32). On the other hand, BCAAs have also been causally linked
to the development of insulin resistance, type II diabetes (33)
and neuropathologies (34). We set out to confirm the marked
upregulation of the BCAA degradation pathway (Table 1; Fig.
S5) at the level of free BCAAs in metformin-treated worms.
Metformin treatment resulted in a significant decrease (-55%) in
the amount of free BCAAs, lending further support to the validity
of the proteomics data (Fig. 4A).
Metabolic flux during metformin treatment
One of the most striking properties of metformin as an an-
tidiabetic in humans, is its ability to cause weight loss in patients,
through, amongst others, activation of the β-oxidation pathway
(2, 35, 36). We observed a 4.3-fold upregulation of the mitochon-
drial acyl-CoA dehydrogenase family member ACDH-1 after
metformin treatment (Dataset S1), defining it as the strongest
upregulated protein by a margin. Acyl-CoA dehydrogenases cat-
alyze the first step in the β-oxidation of fatty acids.
We questioned whether the shift in β-oxidation suggested
by ACDH-1 induction truly occurs and whether it is involved
in metformin-induced lifespan extension. If so, we would grossly
expect overall fat levels to drop in treated worms. Measuring fat
content in L4worms, we found evidence for increased β-oxidation
as metformin-treated worms showed significantly lower (-11,4%)
fat stores (Fig. 4B). A similar reduction in fat content was found
in metformin-treated C. elegans using different methods (5).
To our surprise, acdh-1 knockout worms showed an even
stronger metformin-induced lifespan extension than wild type
worms (Fig. 4C). This implies a more complex interaction be-
tween β-oxidation and metformin (see discussion).
Metformin-treated worms attenuate age-related morpholog-
ical decline.
Aging worms start to show several morphological defects (37)
and shrink in size (38) but metformin-treated worms seemed less
affected by this phenomenon. After measuring several formalin
fixed worms of various ages (Fig. 5A) it became clear that non-
treated worms started losing volume after day 6 of adulthood,
while metformin-treated worms still retained their normal vol-
ume on day 9. Although long-livedmutants are often smaller than
their wild type siblings (39), our results fit the recent observations
that within isogenic populations, the larger animals are generally
the longer-lived ones (38).
Muscle and cuticle are known to show severe morphologi-
cal defects with increasing age in C. elegans (37), making them
prime targets to question whether these tissues are better main-
tained in metformin-treated worms. Our proteomics data already
pointed to an increase in muscle mass and several changes in
the cytoskeleton (Table 1), including upregulation of interme-
diate filament proteins (Dataset S1). Electron micrographs of
9-day-old control and metformin-treated worms displayed no
difference in body wall muscle volume, but there was a clear
difference in cuticle morphology (Fig. 5B-C). While the cuticle of
9-day-old adult non-treated worms started showing signs of age-
related “wrinkling” and disorganization, the cuticle of metformin-
treated worms resembled that of a young animal. Considering
the cuticle’s known role in maintaining the shape and size of
nematodes (40), it can be assumed that it is this amelioration
of cuticle deterioration that allows metformin-treated worms to
retain a healthy, young morphology.
Discussion
We profiled the effect of metformin inC. elegans using a differen-
tial proteomics approach and used the resulting data for further
examination of its beneficial effects and mode of action.
We observed many changes in the mitochondrial proteome,
which might point towards mitonuclear protein imbalance (41)
and an alteredmitochondrial metabolism. It is therefore probable
for metformin to increase lifespan through both the process of
mitohormesis and the induction of the UPRmt. However, met-
formin administration during the larval stages had no effect on
lifespan, while the critical phase forUPRmt induction inC. elegans
is during larval development (24, 42). Because metformin also
proved unable to induce the UPRmt, it is not a likely in vivo
contributor to lifespan extension by metformin in C. elegans.
Contrary to the UPRmt, the mitohormetic pathway is important
for metformin-mediated longevity in this worm.
Hormesis in aging is defined as the process by which a
short-term and nonlethal stressor induces the stress response
mechanisms of an organism and thereby increases stress resis-
tance and overall life expectancy (43). The mitohormetic path-
way, first described in glucose-restricted C. elegans (13), states
that a low availability of ATP - due to low glycolytic activity -
causes activation of AMPK. AMPK in turn promotes general
catabolism and mitochondrial respiration, leading to increased
production of ROS (the hormetic “stressor”), which subsequently
act as messengers to activate further stress defenses, prolonging
lifespan. This contradicts the classical oxidative stress theory of
aging, which postulates that ROS, due to their ability to damage
biomolecules, would be the causative factor of aging (44). We
were able to fully reproduce the mitohormetic phenomenon in
metformin-treated worms and showed that metformin increases
respiration, metabolic heat production and ROS generation in
C. elegans. Inhibition of ROS signaling abolishes the lifespan-
extending effects ofmetformin, proving thatmetformin-mediated
lifespan extension is dependent on the mitohormetic pathway
and most closely resembles the C. elegans response to glucose
restriction.
Though well studied, some major missing links remained in
the mitohormetic pathway, in particular how the ROS signal can
be translated to increased lifespan. We were able to demonstrate
that the C. elegans peroxiredoxin PRDX-2, previously shown to
be involved in peroxide and heavy metal resistance (45), is of
major importance to this function. Peroxiredoxins are a class
of antioxidant proteins characterized by their high susceptibility
to cysteine oxidation (46, 47). PRDX-2 is a typical 2-Cys per-
oxiredoxin (45), of which the active, oxidized form exists as a
homodimer (48). It has recently been shown that these dimers
are subsequently able to oxidize and activate specific substrates,
such as the MAP kinase ASK1 (27), thus resolving how these
proteins might be able to translate ROS signals into downstream
signaling. In the same vein, our experiments revealed increased











































































































































oxidized dimers might activate ASK1’s closest ortholog in C.
elegans, the MAP kinase NSY-1, which functions upstream in the
same signaling pathway as the MAP kinases SEK-1 and PMK-1
(49). This evolutionarily conserved MAP kinase cascade could
ultimately activate several downstream targets that mediate stress
defense, including SKN-1 (28). We showed that prdx-2 is required
for the downstreamactivation of PMK-1 in response tometformin
exposure, completing the pathway (Fig. 6). Therefore, PRDX-2
may well be the protein responsible for translating oxidative stress
into longer lifespan in C. elegans. As the longevity-promoting
effect of exercise in humans also depends on ROS signaling (50),
this pathway may be evolutionary conserved.
AMPK activation is one of the main factors involved in
mitohormetic lifespan extension (13, 26). While metformin is
known to activate AMPK, exactly how this occurs remains elu-
sive. The most common hypothesis is that metformin is able to
partially inhibit complex I of the mitochondrial ETC, which in
turn would lead to energy depletion and activation of AMPK
(19–21). Recently, this has been debated (16, 22). One of the
main arguments against metformin-mediated inhibition of com-
plex I, is the increased activity of pathways that generate energy
after metformin treatment. All these pathways require NAD+
to function, and without efficient recycling of NADH to NAD+,
these pathways are limited in activity. As NADH is mainly re-
cycled at complex I of the ETC, blocking complex I should
lead to an increased NADH/NAD+ ratio and lower catabolism
(Fig. 6). As a case in point, the complex I inhibitor rotenone
indeed increases the NADH/NAD+ ratio (51) and lowers the
activity of the β-oxidation pathway (16). We were able to show
that metformin specifically inhibits complex I of the ETC in
vitro, albeit in a way that seems fundamentally distinct from
rotenone: metformin increased mitochondrial ROS production
while rotenone decreased it. High concentrations of rotenone
reduce the number of electrons that are transferred from NADH
to complex I (high NADH/NAD+ ratio), hence less electrons can
leak out to form ROS. Our results imply that upon metformin
treatment, NADH is still able to transfer its electrons, but these
are subsequently lost, resulting in increasedROSproduction (Fig.
6). Based on these data, we suggest that metformin activates
AMPK through inhibition of complex I (Fig. S6), which leads
to an increase in respiration and a concomitant upregulation of
several catabolic pathways - e.g. β-oxidation, glycolysis, BCAA
catabolism and others - to provide the necessary substrate for the
ETC. Likely exacerbated by metformin-mediated perturbation of
electron transport, the increase in respiration ultimately leads to
amitohormetic increase in ROS production in vivo (Fig. 6). As el-
evated respiration under physiologically normal conditions often
leads to a reduction in ROS production (31), this indeed implies a
direct involvement ofmetformin in the observed increase inROS.
Treatment of C. elegans with metformin results in an over-
all upregulation of several pathways and processes (including
glycolysis and the TCA cycle), most of which are involved in
catabolism, supporting the shift towards increased respiration.
Two catabolic pathways stood out after metformin treatment:
β-oxidation, through the short chain acyl-CoA dehydrogenase
ACDH-1, and BCAA degradation. In light of metformin’s in-
hibitory action on complex I but not complex II of the ETC,
the observed increase in β-oxidation seems a logical adapta-
tion as it produces a relatively high amount of the complex II
substrate FADH2 compared to other catabolic pathways. This
might explain why knocking out acdh-1 adds to the lifespan
increase induced by metformin: high activity of the β-oxidation
pathway could temporarily increase ATP levels and inactivate
AMPK (Fig. 6; Fig. S6). As such, deletion of acdh-1 could cause
a more stringent activation of the mitohormetic pathway. Further
experiments will be needed to fully explore the role of β-oxidation
in metformin-induced lifespan extension. Our results suggest
that the metformin-mediated increase in β-oxidation is likely a
compensatorymechanism that is unrelated tometformin-induced
longevity.
As for the BCAA degradation pathway, no clear singular
correlation between BCAAs and longevity has yet been found in
any organism. While some evidence points towards BCAAs as
a metabolic signature of long life in C. elegans insulin receptor
mutants (31, 32), other studies have causally linked BCAAs to
the development of insulin resistance, diabetes (33) and neu-
ropathologies (34). Interestingly, BCAAs - leucine in particular
- are potent activators of the target of rapamycin (TOR) ki-
nase. Leucine deprivation has previously been associated with
reduced TOR signaling (52), which can in turn prolong lifespan
and is required for DR-mediated lifespan extension (53). Yet, it
remains unclear whether the drop in BCAA levels is necessary for
metformin-induced lifespan extension. The reduction in BCAA
concentrationmight result in lower RNA translation into protein,
both through inactivation of TOR and a reduction in the amount
of substrate necessary for translation (Fig. S6). This in turn may
lead to an increase in longevity. There is some precedence for
this hypothesis, as amino acid imbalance has been associated
with increased longevity inDrosophilamelanogaster (54), amongst
others (55). The recently described bacteria-specific effect of
metformin on longevity in C. elegans (6) might similarly depend
on an amino acid imbalance that occurs through the lowered
production of methionine in metformin-treated bacteria (Fig.
S6). Our results suggest a hitherto unexplored role for the BCAA
degradation pathway in longevity.
Metformin not only increases lifespan, but also healthspan
of C. elegans: treated worms retain a youthful morphology for a
longer time. How metformin is able to attenuate morphological
decline of the cuticle in C. elegans remains elusive, but the inter-
mediate protein IFC-2 (upregulated after metformin treatment,
Dataset S1) seems particularly promising as it is required for nor-
mal body shape and cuticle strength (56). Integrity of the cuticle
and epidermis might play a more important role in longevity than
is generally thought. Deterioration in cuticle structure leads to a
loss in barrier function, which may be one of the causes of death
of older nematodes (37, 40).
In conclusion, this work reveals new insights in the process
of aging, and shows that metformin extends lifespan through
mitohormesis. A missing link in the mitohormesis pathway in
C. elegans has now been assigned: the peroxiredoxin PRDX-
2, a protein that translates a ROS signal into a pro-longevity
cue. Since peroxiredoxin signaling is evolutionary conserved (27),
peroxiredoxins might hold a similar function in humans.
Materials and Methods
C. elegans strains
The following strains were obtained from the Caenorhabditis Genetics
Center (CGC, University of Minnesota): wild type N2, VC289 prdx-2(gk169),
VC1011 acdh-1(ok1489) and SJ4100 zcIs13[hsp-6::GFP]. GA507 glp-4(bn2ts)
daf-16(mgDf50) was provided by the Gems lab. Strains were cultivated on
standard nematode growth medium (NGM) seeded with E. coli OP50. All
strains were outcrossed at least four times, with the exception of SJ4100,
which was outcrossed three times. The outcrossed prdx-2(gk169) and acdh-
1(ok1489) strains were renamed LSC555 and LSC556 respectively. All experi-
ments were performed at 20°C unless stated otherwise.
Sampling for 2D-DIGE
The protein samples for 2D-DIGE were taken from glp-4(bn2ts) daf-
16(mgDf50) worms grown in liquid cultures. The glp-4(bn2ts) mutation con-
fers sterility at the permissive temperature of 24°C avoiding contamination
with progeny. Preventing germline development also removes abundant
contaminating proteins that have no bearing on lifespan, facilitating the
analyses. Since glp-4mutations cause a slight DAF-16 dependent lifespan in-
crease in C. elegans cultured on dead E. coli (57), glp-4(bn2ts) daf-16(mgDf50)
double mutants were used. This does not interfere with the envisaged
results, as lifespan extension due to metformin is independent of DAF-
16 (5). Cultivating the worms in liquid cultures allowed full control over
metformin dosagewhile ensuring that all wormswere fully fed. Additionally,
the high-density samples obtained from liquid cultures ensure high protein











































































































































Worms were synchronized by isolating eggs from gravid adults through
hypochlorite and NaOH treatments (58) and a subsequent sucrose density
centrifugation to separate eggs from dead worms and bacterial debris.
L1 worms were added to Fernbach flasks containing S medium (59) and
constantly shaken at 24°C. Flash frozen E. coli K12 bacteria (Artechno, Isnes,
Belgium) were added to the cultures as food source. The concentration
of bacteria was checked twice a day and new K12 bacteria were added
accordingly to maintain the cultures at optimal food levels (OD550 = 1.8). The
density of worms in the culture never exceeded 1000 worms/mL to prevent
large fluctuations in food availability. When worms reached the L4 stage,
cultures were supplemented with 2′-deoxy-5-fluorouridine (FUdR, Sigma-
Aldrich) at a final concentration of 100 mg/L. This ensures complete sterility,
as glp-4(bn2ts) daf-16(mgDf50) worms rarely manage to still produce a few
eggs. Once worms reached the adult stage, the test group was exposed to
25 mM of metformin (1,1-dimethylbiguanide hydrochloride, Sigma-Aldrich)
for 24 h (see SI Materials and Methods for the determination of the optimal
metformin concentration in liquid media; Fig. S7) and protein samples were
subsequently taken (see SI Materials and Methods for a complete protocol
on protein extraction).
2D-DIGE
Samples were labeled, separated and analyzed as described in Bogaerts
et al. (60). In short, metformin-treated and non-treated protein extracts were
differentially labeledwith either Cy3 or Cy5 fluorescent dyes (GE Healthcare).
A possible dye bias was taken into account by integrating a dye swap into
the experimental design. Differentially labeled samples were pooled, an
internal standard labeled with Cy2 was added and the pooled samples were
separated in two dimensions. Gels were scanned using an Ettan DIGE Imager
(GE Healthcare) and DeCyder 7.0 (GE Healthcare) was used to statistically
analyze the images. Spot intensity was compared using a standard Student’s
t-test with false positive rate correction.
Trypsin digestion and identification of differential proteins
Differential spots were excised using an automated spotpicker (GE
Healthcare). The proteins in each spot were digested using a standard in-gel
trypsin digestion protocol and subsequently identified using peptide mass
fingerprinting (see SI Materials and Methods for a complete protocol).
Clustering of differential proteins
Wormbase gene IDs of differential proteins were uploaded to the
bioinformatic tool DAVID (23) to look for enrichment in functional clusters.
Functional clustering was performed with high stringency. Pathway enrich-
ment was determined using DAVID by querying the Kyoto Encyclopedia of
Genes and Genomes (KEGG).
Lifespan experiments
All lifespan experiments were performed on NGM agar plates or NGM
plates supplemented with or without 50 mM of metformin. NAC was used
at a concentration of 5 mM and BHA at a concentration of 25 µM, when
applicable. For the experiment using BHA, the compound was added from a
1000x concentrated stock in DMSO and an equal volume of DMSOwas added
to the respective controls. The worms used in the BHA lifespan experiment
were pretreated with 25 µM of BHA for one generation before the start
of the experiment. For lifespan experiments, twenty L4 stage worms from
a synchronous culture were transferred to a plate (either regular NGM or
NGM containing one or multiple of the tested compounds), allowed to lay
eggs for 24 h and were then removed from the plate. The progeny was
transferred to a new plate when they reached the young adult stage and
were transferred to new plates during each day of their reproductive period
and every 3 days thereafter. Lifespan was monitored every day starting from
day 1 of the adult stage: animals that didn’t move when gently prodded
were marked as dead. Animals that crawled off the plate or died of vulval
bursting or internal hatching were censored. Survival curves were statisti-
cally analyzed using a Cox Proportional Hazard (to compare the effect of
metformin between strains and/or conditions) or LogRank test (to compare
a single curve to control; corrected for multiple testing using the Benjamini-
Hochberg method). Complete information regarding lifespan experiments
can be found in the supplemental data (Table S1).
Measuring hsp-6::GFP fluorescence
Synchronized L1 worms of the SJ4100 zcIs13[hsp-6::GFP] strain were
transferred to agar plates containing 0 mM, 50 mM or 100 mM of added
metformin. As a positive control, worms were transferred to plates seeded
with HT115 E. coli containing an RNAi construct targeted against cco-1 (24).
To rule out a specific effect of HT115, plates seeded with HT115 containing
an empty vector were used, which caused no fluorescence. Images were
acquired using a Zeiss Axio Imager Z1 microscope.
Measuring metabolic heat and respiration
Metabolic activity and respiration measurements were carried out as
previously described (61). In short, respiration andmetabolic heat production
of synchronized day 1 adult worms were measured using a Clark-type
electrode respirometer (Strathkelvin, Glasgow, Scotland) and a Thermal Ac-
tivity Monitor (Thermometric, Järfälla, Sweden) respectively. Treated worms
were exposed to 50 mM metformin starting from the L1 stage. Oxygen
consumption rates were measured over a span of 15 minutes. After thermal
equilibration of the calorimeter, live heat output of each sample was aver-
aged over a 3-hour period. All data were normalized based on the protein
concentration in each sample, as this directly correlates to worm biomass.
Protein concentrations were determined using a bicinchoninic acid (BCA) kit
(Thermo Scientific). Student’s t-tests were used to statistically analyze the
data.
Quantifying in vivo hydrogen peroxide production
Endogenous hydrogen peroxide production was quantified using the
Amplex Red hydrogen peroxide kit (Invitrogen, Cat# A22188). Adult worms
were washed 3 times with S basal (59), after which the worms were pelleted
through centrifugation (800 g, 3 min). From this dense pellet, 50 µl of
worms were transferred to a new microcentrifuge tube containing 450 µL
of reaction buffer (sodium phosphate buffer supplied with the kit). After
centrifugation (800 g, 1.5 min), the reaction buffer was replaced with fresh
reaction buffer and 500 µL of Amplex Red working solution (prepared
according to the manufacturer’s instructions) was added. The worms were
allowed to rotate in the dark for one hour, after which they were pelleted
through centrifugation (800 g, 1.5 min) and 100 µL of supernatant was
transferred to a fluorescence-compatible 96-well plate. Fluorescence (Ex 550
nm, Em 590 nm) was measured and the worm pellet was subjected to protein
extraction for normalization. Welch’s t-tests with multiple testing correction
(Benjamini-Hochberg) were used to statistically analyze the heteroscedastic
data.
Measuring mitochondrial respiration
Mitochondria were extracted from worms as previously described (62).
Oxygen consumption of the extracted mitochondria was determined using
a Clark-type electrode (Oxygraph 2k) and DatLab software (Oroboros in-
struments, Innsbruck, Austria). An aliquot of 25 µL of mitochondria was
incubated in 2mL of air-saturated MiR05 (0.5 mM EGTA, 3 mM MgCl2, 60
mM K-lactobionate, 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES, 110 mM
sucrose, 1 g/L BSA, pH 7.1) at 20°C. The effect of 25 mM of metformin on
electron transport from complex I and complex II was measured as follows:
(i) metformin was added from a 1.5 M stock (dissolved in MiR05) until a final
concentration of 25 mM was reached (ii) the complex I substrates pyruvate
and malate were added from a 1 M stock until a final concentration of 5 mM
was reached (iii) ADP was added from a 10 mM stock to initiate complex I
respiration (final concentration 25 µM) (iv) when applicable, rotenone was
added as positive control at a final concentration of 1 µg/mL froma 400 µg/mL
stock (v). To initiate complex II respiration, succinate was added from a 1 M
stock until a final concentration of 5 mM was reached.
Measuring mitochondrial hydrogen peroxide production
Mitochondrial hydrogen peroxide production was quantified using a
protocol based on the Amplex Red hydrogen peroxide kit (Invitrogen, Cat#
A22188). A fluorescence-compatible 96-well plate was prepared and several
wells were filled with 96 µL of incubation medium (4 mM ADP, 10 mM
pyruvate, 10 mM malate, 10 U Cu/ZnSOD) either containing no additional
substance, 25 mM of metformin or 1 µg/mL of rotenone. Subsequently, 100
µL of Amplex Red reaction buffer (100 µM Amplex Red, 4 U/mL horseradish
peroxidase dissolved in the sodium phosphate buffer supplied with the kit)
was added followed by the addition of 4 µL of freshly extracted mitochon-
dria. The plate was shaken in the dark and every 2 minutes, fluorescence (Ex
550 nm, Em 590 nm) was measured over the span of 1 hour in order to ac-
curately plot the increase in fluorescence over time resulting from hydrogen
peroxide production. The resulting curves were statistically analyzed using
an ANCOVA analysis.
Anti-PRDX-2 Western blot
A non-reducing anti-PRDX-2 Western blot was performed as described
in Oláhová et al. (45). In short, synchronized L1 worms were grown on NGM
plates with or without 50 mM of added metformin. Proteins were extracted
from young adult worms and separated on a non-reducing SDS-PAGE gel.
Rabbit anti-PRDX-2 antibodies were kindly provided by Dr Elizabeth Veal.
Intensity of PRDX-2 bands was normalized against total protein content of
each lane, which was visualized using a Deep Purple (GE Healthcare) total
protein stain. A Welch’s t-test was performed to analyze the data.
Anti phospho-PMK-1 Western blot
N2 and prdx-2 worms were synchronized and grown on regular NGM
plates. Protein samples of day 1 adult worms were taken as described
for the 2D-DIGE experiment. Proteins were separated on an SDS-PAGE gel
and rabbit anti-phospho-p38 antibodies were used for visualization (Cell
Signaling Technology). Blots were re-incubated with rabbit anti-histone H3
antibodies (Abcam) as a loading control (63).
Measuring fat content through Oil red O staining
Synchronized L1 worms were cultivated on NGM plates with or without
50mMof addedmetformin. L4 stagewormswere harvested and stainedwith
Oil red O. The staining intensity was acquired for at least 30 worms for each
condition (see SI Materials and Methods). A Student’s t-test was performed
to analyze the data.
Measuring worm volume
Wild type worms were synchronized through hypochlorite treatment
and L1 worms were transferred to normal NGM plates or NGM plates
supplemented with 50 mM of metformin. FUdR was added to the plates
when worms reached the L4 stage at a final concentration of 50 µM. For
sampling, worms were washed twice with S basal and subsequently fixed in
4% formaldehyde (3 min at 65°C). Images of the formaldehyde fixed worms
were captured and worm width (D) and length (L) were analyzed using a
RapidVUE® Particle Shape and Size Analyzer (Beckman Coulter, Pasadena,













































































































































Wild type worms were synchronized and sterilized as described for the
volume measurements. Worms were harvested when they reached day 9
of adulthood and prepared for electron microscopy (see SI Materials and
Methods).
Quantifying concentration of branched-chain amino acids
Wild type worms were synchronized and L4 worms were harvested from
the plates. BCAA concentration was measured using a BCAA assay kit (Sigma-
Aldrich, Cat# MAK003) according to manufacturer’s instructions. Total pro-
tein content of the extracts was quantified using the Qubit Protein Assay
(Invitrogen) and used for normalization. A Welch’s t-test was performed to
analyze the data.
Statistical analysis
All statistical analyses, apart from the DeCyder and DAVID analysis,
were carried out using R (64). All bar graphs show the mean of biologically
independent samples, error bars show SEM. P-values < 0.05 were considered
significant.
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